Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1

被引:0
|
作者
Bennink, Herjan J. T. Coelingh [1 ]
Roos, Erik P. M. [2 ]
van Moorselaar, R. Jeroen A. [3 ]
van Melick, Harm H. E. [4 ]
Somford, Diederik M. [5 ]
Roeleveld, Ton A. [6 ]
de Haan, Tjard D. [7 ]
Reisman, Yacov [8 ]
Schultz, Iman J. [1 ]
Krijgh, Jan [1 ]
Debruyne, Frans M. J. [9 ]
机构
[1] Pantarhei Oncol, NL-3700 AL Zeist, Netherlands
[2] Antonius Hosp, Dept Urol, NL-8601 ZK Sneek, Netherlands
[3] Free Univ Amsterdam, Dept Urol, Amsterdam UMC, NL-1081 HV Amsterdam, Netherlands
[4] St Antonius Hosp, Dept Urol, NL-3435 CM Nieuwegein, Netherlands
[5] Canisius Wilhelmina Hosp, Dept Urol, NL-6532 SZ Nijmegen, Netherlands
[6] North West Hosp, Dept Urol, NL-1815 JD Alkmaar, Netherlands
[7] Isala Hosp, Dept Urol, NL-8025 AB Zwolle, Netherlands
[8] Flare Hlth, NL-1012 DA Amsterdam, Netherlands
[9] Andros Clin, NL-6803 AA Arnhem, Netherlands
关键词
androgen deprivation therapy (ADT); PCombi study; estetrol (E4); follicle-stimulating hormone (FSH); insulin-like growth factor-1 (IGF-1); ANDROGEN DEPRIVATION THERAPY; HORMONE; TESTOSTERONE; PROGRESSION;
D O I
10.3390/jcm13195996
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The co-treatment of androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) with the fetal estrogen estetrol (E4) may further inhibit endocrine PCa tumor stimulators. We previously reported the suppression of follicle-stimulating hormone (FSH), total and free testosterone, and prostate-specific antigen by ADT+E4. Here, we provide more detailed data on FSH suppression by E4 and present new findings on the effect of ADT+E4 on insulin-like growth factor-1 (IGF-1). Methods: A Phase II, double-blind, randomized, placebo-controlled study (the PCombi study) was conducted in advanced PCa patients treated with ADT. The study assessed the effect of E4 co-treatment with LHRH agonist ADT on tumor stimulators, including FSH and IGF-1. Patients starting ADT were randomized 2:1 to receive either 40 mg E4 (n = 41) or placebo (n = 21) for 24 weeks. Non-parametric analyses were performed on the per-protocol population (PP) and individual changes were visualized. Results: The PP included 57 patients (37 ADT+E4; 20 ADT+placebo). ADT+E4 almost completely suppressed FSH in all patients (98% versus 37%; p < 0.0001). IGF-1 levels decreased by 41% with ADT+E4 versus an increase of 10% with ADT+placebo (p < 0.0001). Conclusions: The almost complete suppression of the tumor stimulator FSH using ADT plus E4 observed in all individual patients in this study, along with the augmented suppression of IGF-1 versus an increase by ADT only, may be clinically relevant and suggest the enhanced anti-cancer treatment efficacy of E4 in addition to the previously reported additional suppression of total and free T and PSA.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Targeting the IGF-1/IGF-1R signaling in uveal melanoma inhibits cell survival, cell migration and reduces tumor growth
    Chattopadhyay, Chandrani
    Bhattacharya, Rajat
    Roszik, Jason
    Villanueva, Hugo
    Wells, Gabrielle
    Grimm, Elizabeth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [32] IGF-1 is downregulated in experimental cancer cachexia
    Costelli, Paola
    Muscaritoli, Maurizio
    Bossola, Maurizio
    Penna, Fabio
    Reffo, Patrizia
    Bonetto, Andrea
    Busquets, Silvia
    Bonelli, Gabriella
    Lopez-Soriano, Francisco J.
    Doglietto, Giovanni Battista
    Argiles, Josep M.
    Baccino, Francesco M.
    Rossi Fanelli, Filippo
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2006, 291 (03) : R674 - R683
  • [33] Cancer in a patient receiving IGF-1 therapy
    Frank, RN
    Grunberger, G
    DIABETES CARE, 2000, 23 (03) : 435 - 436
  • [34] Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    Wolf, I.
    Levanon-Cohen, S.
    Bose, S.
    Ligumsky, H.
    Sredni, B.
    Kanety, H.
    Kuro-o, M.
    Karlan, B.
    Kaufman, B.
    Koeffler, H. P.
    Rubinek, T.
    ONCOGENE, 2008, 27 (56) : 7094 - 7105
  • [35] Nutrition, GH/IGF-1 signaling, and cancer
    Fanti, Maura
    Longo, Valter D.
    ENDOCRINE-RELATED CANCER, 2024, 31 (11)
  • [36] Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer
    I Wolf
    S Levanon-Cohen
    S Bose
    H Ligumsky
    B Sredni
    H Kanety
    M Kuro-o
    B Karlan
    B Kaufman
    H P Koeffler
    T Rubinek
    Oncogene, 2008, 27 : 7094 - 7105
  • [37] Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the Prostate Cancer Lifestyle Trial
    Dewell, Antonella
    Weidner, Gerdi
    Sumner, Michael D.
    Barnard, R. James
    Marlin, Ruth O.
    Daubenmier, Jennifer J.
    Chi, Christine
    Carroll, Peter R.
    Ornish, Dean
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2007, 58 (01): : 35 - 42
  • [38] Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC)
    Javle, Milind M.
    Shroff, Rachna T.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Fogelman, David R.
    Bhosale, Priya
    Wang, Xuemei
    Kar, Siddhartha P.
    Overman, Michael J.
    Sathyanarayanan, Sriram
    Ayers, Mark
    Mauro, David J.
    Abbruzzese, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Walnuts alter IGF-1 signaling and lipogenesis genes and reduce TRAMP prostate tumor size and growth
    Davis, Paul Andrew
    Vasu, Vihas
    Gohil, Kishor
    Kim, Hyunsook
    Yokoyama, Wallace
    Khan, Imran
    Cross, Carroll
    FASEB JOURNAL, 2010, 24
  • [40] The role of IGF-1 and IGFBP-3 in predicting disease progression in Prostate Cancer patients
    Siabanopoulou, M. T.
    Iakovou, I.
    Zaromitidou, E.
    Ordoulidis, S. El Mantani
    Galaktidou, G.
    Dimasis, N.
    Sioundas, A.
    Gotzamani-Psarrakou, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S576 - S576